From conception to clinical trial: IViST, the first multi-sensor-based platform for real-time In Vivo Source Tracking in HDR brachytherapy

H. M. Linares Rosales1,2, Audrey Cantin1, Sylviane Aubin1, Sam Beddar4, Luc Beaulieu1,2
1Département de physique, de génie physique et d’optique et Centre de recherche sur le cancer, Université Laval, Québec, Canada.
2Département de radio-oncologie et Axe Oncologie du CRCHU de Québec, CHU de Québec - Université Laval, QC, Canada.
3Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
4The University of Texas MD Anderson UTHealth Graduate School of Biomedical Sciences, Houston, TX, United States.

Email: Luc.Beaulieu@PHY.ULAVAL.CA

Abstract. This study is aimed to introduce a novel multi-sensor-based dosimetry platform for real-time plan monitoring in HDR brachytherapy: IViST (In Vivo Source Tracking). IViST is a platform composed of three components: 1) an optimized and characterized multi-point plastic scintillator dosimeter (3 points mPSD; using BCF-60, BCF-12, and BCF-10 scintillators), 2) a compact assembly of photomultiplier tubes (PMTs) coupled to dichroic mirrors and filters for high-sensitivity scintillation light collection, and 3) a Python-based graphical user interface used for system management and signal processing. IViST can simultaneously measure dose, triangulate source position, and measure dwell time. By making 100,000 measurements/s, IViST samples enough data to quickly perform key QA/QC tasks such as identifying wrong individual dwell time, position, or interchanged transfer tubes. By using 3 co-linear sensors and planned information for an implant geometry, the platform can also triangulate source position in real-time. A clinical trial to validate this system is presently on-going using the IViST system.

1. Introduction
In vivo dosimetry (IVD) in brachytherapy (BT) aims to quantify in real-time the agreement between the treatment plan and delivered dose. Presently, BT clinics do not verify their treatments in real-time: (a) commercial real-time IVD systems have small signal-to-noise ratios (SNR) (limited time resolution, large measurements uncertainties, detection of only large errors); (b) laboratory real-time systems can be cumbersome to operate (more difficult to disseminate to BT clinics and workflow); (c) non PSD based detector systems do not employ sophisticated error detection algorithms, large false error rate, poor confidence in error reporting. Several studies [1–8] have been focused on developing detectors and methods for real-time source monitoring in BT. The advantages of using plastic scintillator detectors (PSDs) have been demonstrated and discussed in the literature [9, 10]. Their real-time response being an important advantage for this novel application. Nevertheless, PSDs are affected by stem effect and temperature variations [11, 12]. The proper optimization of the optical chain combined with the
implementation of mathematical methods to correct both dependencies have been implemented within this system [13-15].

The main goal of this study is to clinically validate IViST as a new multi-sensor-based dosimetry platform for real-time plan monitoring in HDR brachytherapy.

2. IViST: the platform
IViST is a novel platform composed of 3 components: 1) a mPSD, 2) a light collection system, and 3) a Python-based graphical user interface (GUI) used for system management and signal processing. IViST can simultaneously measure dose, triangulate source position, and measure dwell time.

2.1 Dosimetry system
The optimized dosimetry system consisted of a 1.0 mm-diameter core mPSD (using BCF-60, BCF-12, and BCF-10 scintillators) coupled to 15 m-long fiber-optic cable EskaGH-4001 from Mitsubishi Rayon Co., Ltd. (Tokyo, Japan). The mPSD fiber was connected to a data acquisition system consisting of a compact assembly of photomultiplier tubes (PMTs) coupled with dichroic mirrors and filters to achieve a highly sensitive scintillation light collection [15]. The scintillation light generated inside the mPSD is collected in real-time and decoupled using multiple spectral bands [14, 15]. The PMTs readout is independent from the irradiation unit. Signal acquisition is made at a rate of 100 kHz using a data acquisition board (DAQ) type DAQ NI USB-6216M Series Multifunction from National Instruments (Austin, USA).

![IViST's dosimetry system](image)

**Figure 1.** IViST’s dosimetry system. A detailed list of sub-components can be found in Linares Rosales et al [16].

The design of the in vivo dosimetry system is shown in figure 1. The detector was made light-tight to avoid environmental light. The mPSD can be inserted into a 24-cm plastic catheter (Best Medical International, Springfield, VA, USA). In vivo measurements can be made using a supplemental catheter during HDR brachytherapy. The light collection apparatus was enclosed into a plastic custom-made box (43.2 x 38.1 x 18.42 cm³) containing the light acquisition system as well as the DAQ. It is a passive light collection system that does not represent any electrical risk. The system’s dosimetric performance have been evaluated in HDR brachytherapy, covering a range of 10 cm of source movement around the sensors [15,16]. Within a range of distances of 6 cm from the source, IViST can track the 192Ir source with at least a 1 mm positional accuracy, and dose agreement with TG43-U1 [17] expected dose within
5 % [16]. The detector further exhibited no angular dependence and the system high collection rate allows for dwell time assessment with a maximum average weighted deviation of 0.33±0.37s [16].

2.2 Graphical user interface for dosimetry system control
Figure 2 illustrates the graphical user interface (GUI) of the key software tools available to control the dosimetry system. The GUI was designed for simple operation by any users. PyQt5 was used to create the GUI. Figure 3 summarizes the main functionalities of the GUI and the relationship among them. The software’s main windows give the user access to 2 main modes: Offline and In vivo.

Within Offline tools:

- **Signal processing**: A measurement file is loaded in this module by the user. Then, the module allows for easy extraction and manipulation of the raw data previously collected. It can also be used to extract the statistics associated with each dwell position (e.g. measured dwell time, mean raw signal, mean dose per dwell).
- **System calibration**: The module receives a measurement data set, and based on TG43’s expected dose, generates the calibration models for raw signal translation into a dose value. Among the main features of this module, it allows for dose prediction with the hyper-spectral approach proposed in [14] as well as a Random Forest algorithm and Neural Network
- **Dosimetry tools**: Performs the dosimetric analysis of the collected data. The user could, for instance, verify the agreement of the measured dose with that expected from TG43 and calculate the source position for the measured plan. The module also includes a catheter shift correction feature.

![Figure 2](image_url)

**Figure 2.** IViST’s graphical user interface. Illustration of some of the available functionalities.

The In Vivo Dosimetry module contains the tools used for real-time data acquisition:

- **Voltage acquisition**: Collects the raw measurement data from each PMT in volts.
- **Dose measurement** is a similar to the offline module, excepting that a calibration data file has to be available in advance.
- **Real time plan monitoring:** Performs real-time tracking of a patient plan created in Oncentra Prostate and Oncentra Brachy (Nucletron, Elekta, Sweden). The module reads the plan data contained in the *.cha or DICOM RT files exported from the TPS, sets the treatment data as reference and monitors the patient plan in real-time. The system should be calibrated in advance. The GUI allows for real-time visualization of the measured dose at the mPSD location as well as the source location.

3. **In vivo measurements for a prostate treatment: First Patient Measurements**

In vivo dose monitoring was carried out for the first patient enrolled in an IRB approved protocol. Seventeen treatment catheters were positioned and reconstructed to deliver 15 Gy in a single fraction. An additional catheter devoted to measurements with the mPSD was introduced in the prostate volume. The mPSD’s catheter was also reconstructed, but it was not used during the dose optimization process in the treatment planning system.

![Figure 3. IViST’s codes diagrams.](image)

![Figure 4. Source position triangulation results. Heat map of deviations between the planned position and the triangulated one in a 3D space. The cells in gray correspond to non-programmed dwell positions.](image)
Figure 4 shows the heat map of deviations obtained between the planned source dwell positions and the results from the triangulation with the mPSD. The x-axis corresponds to the dwell position index within each catheter, while the y-axis corresponds to the treatment catheter number. Catheter 8 is not plotted because it corresponds to the catheter dedicated to measurements with the mPSD. In total, 168 source dwell positions were tracked. As could be observed in figure 4, in most of the cases, the radial deviations remain below 3mm. However, there are some dwell positions with deviations reaching 9 mm. This effect could be explained by the small source dwell times, 0.1 s (from the TPS dose optimization process), programmed at these dwell-positions. Figure 5 presents the observed radial deviations as a function of the delivered dwell times for BCF10, BCF12, BCF60 sensors as well as for the mPSD’s triangulation results. As could be observed in figure 5, for dwell times of 0.1 s, radial deviations in the order of 6 mm should be expected. IViST’s data is collected at a rate of 100 kHz but averaged each 0.1 s. Thus a dwell time of 0.1 s makes it almost impossible to distinguish one single dwell position from the previous/subsequent one, leading to a failed source position triangulation for those locations. However, for any dwell-time of 0.5 s or more (which are the majority of the dwell times used in a prostate HDR treatment), the weighted average for source position triangulation is 2.17±1.15 mm.

Figure 4.

Figure 5. Scintillator deviation of the expected source-to-dosimeter radial deviations as a function of the source planned dwell time.

Figure 6.

Figure 6. Deviation of mPSD measured dwell times from planned dwell times as function of planned dwell-time intervals.

Figure 6 shows the mean deviations between the measured dwell times for our mPSD system and the planned ones. The measured dwell times at all the distances to the source were agreement with the
planned dwell time to better than 0.17 s. The overall average difference obtained was 0.06±0.04 s. Larger deviations were observed for dwell positions with dwell times inferior to 0.5 s, especially for those positions at long distances from the scintillators’ effective volumes. Even though the longest mPSD-to-source distance measured for this clinical case was 55 mm, the high gradient field characteristic of the 192Ir source allowed to us obtain a sharp pulse of signal and, as a consequence, proper differentiation of the signal from one position to the subsequent one. A similar dwell time analysis was performed by Linares Rosales [16] et al. through in-water measurements during HDR brachytherapy. They reported a maximum deviation of 0.33±0.37 s for a range of mPSD-to-source distance up to 10 cm. However, for the same range of distance to the explored in this paper, the results are equivalents [16].

4. Conclusions
A novel, multi-sensor dosimetric system was optimized for HDR brachytherapy in vivo dosimetry and enabled measurements over a wide range of clinically relevant dose rate. The system presented allows real-time dose, source position and dwell-time measurements. It has numerous potential in vivo QA/QC applications beyond the currently available commercial dosimeters and build on its widely-known intrinsic energy independence and water equivalence properties. The first clinical in vivo case measured with iViST has been presented here and the clinical trial is on-going.

5. Acknowledgements
This work was supported by the National Sciences and Engineering Research Council of Canada (NSERC) via the NSERC-Elekta Industrial Research Chair grant # 484144-15and RGPIN-2019-05038. Haydee Maria Linares Rosales also acknowledges support from Fonds de Recherche du Quebec -Nature et Technologies (FRQ-NT).

6. References
[1] Fonseca G P, Podesta M, Bellezzo M et al 2017 Phys. Med. Biol. 62 5440
[2] Cartwright L E, Suchowerska N, Yin Y et al 2010. Med. Phys. 37 2247-55
[3] Hardcastle N, Cutajar D L, Metcalfe P E et al 2010 Phys. Med. Biol. 55 3859
[4] Kertzscher G, Andersen C E, Siebert F A et al 2011 Radioth. Oncol. 100 456-62
[5] Seymour E L, Downes S J, Fogarty G et al 2011 Med. Phys. 38 4785-94
[6] Kertzscher G, Andersen C E, Tanderup K 2014 Med. Phys. 41 052102
[7] Johansen J G, Rylander S, Buus S et al 2018 Brachytherapy. 17 122-32
[8] Sethi R, Chun Kuo Y, Edraki B et al 2018 Brachytherapy 17 S114-5
[9] Beaulieu L, Beddar S 2016 Phys. Med. Biol. 61 R305
[10] Beddar S, Beaulieu L (Eds.) 2016 Scintillation Dosimetry. CRC Press. ISBN: 978-1-4822-0900-6
[11] Wootton L, Beddar S 2013 Phys. Med. Biol. 58 2955
[12] Beddar S 2012 Med. Phys. 39 6522-22
[13] Archambault L, Arsenault J, Gingras L et al 2005 Med. Phys. 32 2271-8
[14] Archambault L, Theriault-Proulx F, Beddar S et al 2012 Phys. Med. Biol. 57 7133
[15] Linares Rosales H M, Duguay-Drouin P, Archambault L et al 2019 Med. Phys. 46 2412-21
[16] Linares Rosales H M, Archambault L, Beddar S et al 2020 Med. Phys. 47 4477-90
[17] Rivard M J, Coursey B M, DeWerd et al 2004 Med. Phys. 31 633-74